Arena Rises With Post-Belviq Pipeline

 
• By Mike Ward

Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.

Video interview
Interview with Arena CEO Amit Munshi

More from Strategy

More from Business